MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-09-2026
Becton, Dickinson and Company Financial Ratios 2011-2026 | BDX
Annual Financial Ratios Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
33.5 | 37.6 | 45.6 | 37.7 | 34.2 | 79.8 | 56.0 | 191.6 | 41.5 | 36.6 | 41.5 | 20.8 | 15.9 | 13.2 | 13.9 |
P/S |
2.6 | 3.2 | 3.5 | 3.6 | 3.7 | 4.3 | 4.0 | 3.7 | 3.8 | 2.9 | 2.8 | 2.9 | 2.6 | 2.0 | 2.2 |
EPS |
5.8 | 5.9 | 5.0 | 5.9 | 6.9 | 2.8 | 4.0 | 0.6 | 4.7 | 4.6 | 3.4 | 6.1 | 6.6 | 5.7 | 5.8 |
EV (Enterprise Value) |
55.5 B | 62.4 B | 66.1 B | 66 B | 69.1 B | 66.8 B | 99.2 B | 91.3 B | 56.3 B | 52.1 B | 47.1 B | 30.2 B | 25.8 B | 21 B | 22 B |
EBITDA per Share |
17.5 | 16.2 | 15.4 | 15.8 | 15.5 | 10.8 | 16.6 | 16.3 | 13.3 | 15.4 | 11.8 | 11.2 | 9.23 | 10.1 | 10.3 |
EV/EBITDA |
13.6 | 20.1 | 19.6 | 18.9 | 17.2 | 14.0 | 16.8 | 12.3 | 12.6 | 8.7 | 8.4 | ||||
PEG |
3.01 | 15.15 | 24.9 | 5.48 | 8.99 | 61.08 | 0.1 | -2.21 | 17.33 | 1.08 | -0.94 | -2.76 | 0.97 | -13.63 | 5.99 |
P/B |
1.0 | 1.1 | 1.3 | 1.3 | 1.3 | 1.3 | 3.3 | 2.8 | 3.5 | 4.7 | 4.0 | 4.9 | 4.1 | 3.7 | 3.6 |
P/CF |
- | - | - | - | - | - | 29.1 | 30.2 | 25.1 | 19.4 | 26.3 | 22.6 | 22.4 | 12.8 | 15.9 |
ROE % |
6.61 | 6.59 | 5.75 | 7.04 | 8.84 | 3.68 | 5.85 | 1.48 | 8.50 | 12.78 | 9.70 | 23.45 | 25.64 | 28.29 | 26.32 |
ROA % |
3.03 | 2.98 | 2.81 | 3.36 | 3.88 | 1.62 | 2.38 | 0.58 | 2.92 | 3.81 | 2.59 | 9.52 | 10.64 | 10.30 | 12.19 |
ROCE % |
10.16 | 9.26 | 8.18 | 9.03 | 9.50 | 3.84 | 4.85 | 4.80 | 5.33 | 10.19 | 6.69 | 15.73 | 12.53 | 16.60 | 20.49 |
Current Ratio |
- | - | - | - | - | - | 1.2 | 1.0 | 5.6 | 1.4 | 1.4 | 2.7 | 2.8 | 2.7 | 2.6 |
DSO |
50.4 | 50.4 | 44.5 | 43.9 | 45.3 | 53.9 | 49.5 | 53.0 | 52.6 | 47.3 | 57.4 | 51.3 | 56.2 | 59.2 | 57.3 |
DIO |
118.5 | 117.5 | 105.8 | 104.8 | 95.4 | 104.7 | 104.6 | 102.6 | 107.9 | 96.6 | 128.0 | 131.6 | 131.8 | 120.6 | 121.6 |
DPO |
59.3 | 58.4 | 54.4 | 60.4 | 53.8 | 48.1 | 44.3 | 46.3 | 47.3 | 37.4 | 41.2 | 35.3 | 31.3 | 34.1 | 29.8 |
Operating Cycle |
168.9 | 167.8 | 150.4 | 148.7 | 140.7 | 158.6 | 154.1 | 155.5 | 160.5 | 144.0 | 185.4 | 182.9 | 188.0 | 179.8 | 178.9 |
Cash Conversion Cycle |
109.6 | 109.4 | 96.0 | 88.3 | 86.9 | 110.4 | 109.8 | 109.3 | 113.2 | 106.6 | 144.2 | 147.6 | 156.7 | 145.7 | 149.1 |
All numbers in USD currency
Quarterly Financial Ratios Becton, Dickinson and Company
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.34 | 2 | 1.07 | 1.05 | 1.68 | 1.85 | 0.97 | 1.37 | 1.54 | 1.71 | - | 1.18 | 1.51 | 2.3 | - | 1.73 | 0.95 | 3.38 | 0.36 | 0.98 | 3.38 | 0.88 | 0.46 | 1.53 | 0.88 | 2.09 | -0.64 | 2.08 | 2.09 | -0.76 | 1.27 | -0.75 | -0.76 | 2.64 | 0.09 | 1.83 | 2.64 | 1.08 | 0.86 | 0.3 | 1.08 | 1.22 | 1.56 | 1.69 | 1.22 | 1.4 | 6.16 | 1.55 | 1.4 | 3.18 | 4.24 | 1.62 | 3.18 | 1.23 | 4.36 | 1.57 | 1.23 |
EBITDA per Share |
4.08 | 4.45 | 3.28 | 3.66 | 3.33 | 3.8 | 3.45 | 3.2 | 3.5 | 4.06 | - | 3.13 | 3.21 | 4.35 | - | 6.01 | 2.69 | 6.18 | 10.3 | 5.05 | 6.18 | 3.8 | 12.4 | 6.48 | 3.8 | 5.39 | 9.2 | 5.06 | 5.39 | 2.29 | 8.51 | 1.36 | 2.26 | 5.04 | 10.2 | 5.09 | 5.04 | 3.03 | 6.79 | 1.97 | 3.03 | 2.53 | 8.35 | 3.71 | 2.53 | 2.68 | 8.1 | 3.44 | 2.68 | 2.65 | 7.48 | 3.51 | 2.65 | 2.19 | 3.99 | 0.92 | 2.31 |
ROE % |
6.19 | 6.56 | 6.40 | 6.29 | 6.65 | 6.56 | 6.47 | 5.36 | 5.64 | 5.70 | 6.50 | 6.83 | 9.00 | 8.42 | 7.50 | 8.04 | 7.07 | 10.03 | 7.27 | 7.51 | 8.44 | 5.54 | 7.03 | 5.61 | 6.30 | 7.84 | 4.40 | 7.57 | 3.72 | -0.18 | 7.87 | 5.59 | 11.72 | 20.13 | 15.89 | 18.17 | 13.93 | 9.76 | 11.25 | 14.68 | 20.26 | 21.74 | 22.42 | 40.31 | 39.85 | 40.65 | 49.30 | 46.74 | 48.66 | 58.31 | 49.89 | 48.70 | 47.90 | 38.23 | 20.11 | 7.11 | 5.45 |
ROA % |
2.86 | 3.04 | 2.99 | 2.96 | 3.17 | 3.14 | 3.11 | 2.57 | 2.63 | 2.62 | 2.93 | 3.06 | 4.03 | 3.76 | 3.35 | 3.59 | 3.15 | 4.46 | 3.16 | 3.24 | 3.58 | 2.26 | 2.85 | 2.29 | 2.52 | 3.09 | 1.72 | 2.83 | 1.38 | -0.09 | 2.47 | 1.68 | 3.55 | 6.11 | 4.67 | 5.28 | 3.99 | 2.66 | 3.06 | 4.81 | 7.19 | 8.22 | 9.20 | 16.67 | 16.54 | 16.91 | 20.03 | 17.89 | 18.28 | 21.51 | 18.44 | 20.00 | 20.41 | 17.42 | 9.31 | 3.29 | 2.52 |
ROCE % |
9.61 | 9.75 | 9.15 | 8.72 | 9.04 | 9.16 | 8.59 | 6.86 | 7.04 | 6.90 | 7.46 | 7.77 | 10.37 | 9.90 | 9.47 | 14.64 | 13.54 | 16.93 | 14.26 | 16.91 | 18.38 | 15.53 | 17.32 | 13.94 | 13.41 | 15.26 | 12.22 | 15.77 | 11.61 | 9.15 | 18.74 | 28.23 | 36.71 | 45.56 | 39.74 | 33.13 | 28.28 | 22.57 | 24.59 | 37.54 | 44.43 | 46.43 | 46.98 | 46.52 | 45.74 | 46.33 | 47.66 | 52.56 | 55.39 | 57.37 | 55.73 | 53.41 | 51.81 | 49.76 | 25.95 | 9.26 | 7.43 |
DSO |
47.4 | 49.5 | 49.0 | 46.2 | 47.1 | 43.6 | 45.4 | 45.1 | 44.4 | 44.5 | - | 22.6 | 43.0 | 45.2 | - | 42.7 | 45.2 | 40.9 | 45.7 | 56.8 | 38.4 | 47.7 | 46.7 | 49.2 | 49.2 | 49.7 | 48.1 | 49.5 | 46.7 | 55.5 | 50.3 | 52.4 | 50.1 | 49.0 | 45.7 | 45.5 | 48.2 | 47.8 | 48.7 | 47.7 | 40.5 | 49.3 | 49.2 | 50.2 | 51.2 | 53.3 | 19.0 | 55.1 | 54.5 | 58.0 | 19.9 | 57.6 | 57.4 | 59.0 | 20.0 | 57.4 | - |
DIO |
129.0 | 121.8 | 114.8 | 110.7 | 110.3 | 108.7 | 117.4 | 119.0 | 128.1 | 127.0 | - | 57.8 | 108.9 | 107.8 | - | 97.2 | 97.4 | 98.2 | 36.0 | 114.0 | 97.2 | 108.4 | 35.2 | 103.4 | 103.6 | 103.8 | 34.9 | 98.9 | 113.0 | 143.0 | 36.5 | 108.3 | 104.7 | 105.9 | 32.6 | 95.0 | 115.0 | 114.0 | 45.2 | 91.9 | 100.4 | 136.4 | 44.8 | 130.4 | 134.3 | 133.6 | 44.6 | 128.8 | 128.6 | 132.7 | 40.6 | 119.5 | 127.7 | 127.0 | 42.8 | 123.1 | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | 32.8 | - | - | - | 23.9 | 8.9 | - | - | 22.2 | 7.5 | - | - | 23.1 | 7.9 | - | - | 23.8 | 8.0 | - | - | 20.6 | 6.3 | - | - | 18.2 | 7.3 | - | - | 18.2 | 6.0 | - | - | 15.5 | 5.3 | - | - | 17.9 | 5.7 | - | - | 15.4 | 5.2 | - | - |
Operating Cycle |
176.4 | 171.2 | 163.8 | 156.9 | 157.4 | 152.4 | 162.8 | 164.1 | 172.5 | 171.5 | - | 80.4 | 151.9 | 153.0 | - | 139.9 | 142.6 | 139.1 | 81.7 | 170.8 | 135.6 | 156.1 | 81.9 | 152.6 | 152.8 | 153.5 | 83.0 | 148.3 | 159.7 | 198.4 | 86.8 | 160.7 | 154.8 | 154.8 | 78.3 | 140.6 | 163.2 | 161.9 | 93.8 | 139.6 | 140.8 | 185.7 | 94.0 | 180.6 | 185.5 | 186.8 | 63.6 | 183.9 | 183.1 | 190.8 | 60.5 | 177.1 | 185.1 | 186.0 | 62.8 | 180.6 | - |
Cash Conversion Cycle |
176.4 | 171.2 | 163.8 | 156.9 | 157.4 | 152.4 | 162.8 | 164.1 | 172.5 | 171.5 | - | 80.4 | 151.9 | 120.2 | - | 139.9 | 142.6 | 115.2 | 72.8 | 170.8 | 135.6 | 134.0 | 74.4 | 152.6 | 152.8 | 130.4 | 75.1 | 148.3 | 159.7 | 174.6 | 78.8 | 160.7 | 154.8 | 134.2 | 72.0 | 140.6 | 163.2 | 143.6 | 86.6 | 139.6 | 140.8 | 167.5 | 88.0 | 180.6 | 185.5 | 171.3 | 58.3 | 183.9 | 183.1 | 172.9 | 54.7 | 177.1 | 185.1 | 170.5 | 57.6 | 180.6 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Becton, Dickinson and Company, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
$ 29.4 | 2.58 % | $ 1.4 B |  USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
$ 79.94 | 0.25 % | $ 40.4 B |  Schweiz |
 |
Ekso Bionics Holdings
EKSO
|
$ 10.0 | 3.84 % | $ 24.3 M | USA |
 |
The Cooper Companies
COO
|
$ 71.61 | -0.13 % | $ 14.3 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 60.48 | 2.04 % | $ 3.04 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 123.23 | 2.31 % | $ 3.94 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.3 | -0.92 % | $ 199 M | USA |
 |
Harvard Bioscience
HBIO
|
$ 4.91 | 5.48 % | $ 218 M | USA |
 |
electroCore
ECOR
|
$ 6.55 | 4.22 % | $ 55.6 K | USA |
 |
Microbot Medical
MBOT
|
$ 2.43 | 3.4 % | $ 111 M |  Israel |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 70.54 | -0.04 % | $ 4.17 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 120.52 | 0.86 % | $ 5.84 B | USA |
 |
Masimo Corporation
MASI
|
$ 178.39 | -0.04 % | $ 9.51 B | USA |
 |
ICU Medical
ICUI
|
$ 127.85 | -1.14 % | $ 3.15 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | 1.74 % | $ 23.8 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.99 | 2.67 % | $ 206 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 27.38 | 1.75 % | $ 4.6 B | USA |
 |
Pro-Dex
PDEX
|
$ 52.77 | 0.71 % | $ 173 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 467.22 | 1.8 % | $ 167 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 117.39 | 1.93 % | $ 2.66 B | USA |
 |
BioLife Solutions
BLFS
|
$ 20.27 | 0.8 % | $ 934 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.67 | -3.55 % | $ 20.1 M | USA |
 |
Baxter International
BAX
|
$ 17.59 | -0.23 % | $ 9.02 B | USA |
 |
ResMed
RMD
|
$ 230.69 | 0.19 % | $ 33.7 B | USA |
 |
STERIS plc
STE
|
$ 224.83 | -0.01 % | $ 22.2 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 20.12 | 6.34 % | $ 1.36 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 125.21 | 1.65 % | $ 5.59 B | USA |
 |
Stereotaxis
STXS
|
$ 2.03 | 5.73 % | $ 185 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 24.43 | -8.98 % | $ 1.21 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Utah Medical Products
UTMD
|
$ 68.37 | 1.82 % | $ 222 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 12.22 | 1.66 % | $ 2.44 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 267.93 | 3.07 % | $ 19.4 B | USA |
 |
AngioDynamics
ANGO
|
$ 10.47 | 2.25 % | $ 428 M | USA |
 |
Nephros
NEPH
|
$ 2.88 | -1.03 % | $ 29.9 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.21 | 4.22 % | $ 236 M | USA |
 |
Repligen Corporation
RGEN
|
$ 131.03 | 6.88 % | $ 7.3 M | USA |